More on Sangamo BioSciences' (SGMO) Q2: Collaboration agreements with Shire and Sigma-Aldrich...


More on Sangamo BioSciences' (SGMO) Q2: Collaboration agreements with Shire and Sigma-Aldrich account for $6.2M of the $6.9M in revenue the company recognized during the period with the balance consisting of research grants. SGMO's collaboration with Shire brings in $4.7M during the quarter. R&D expenses rise 22% Y/Y on "increased external expenses related to … preclinical programs." FY13 guidance: Revenue of $20-24M, $46-50M in operating expenses, and cash and cash equivalents of "at least" $55M by the end of the year. Shares +1.19% AH. (PR)

From other sites
Comments (1)
  • MineMan
    , contributor
    Comments (599) | Send Message
     
    $1.5 million in revs from SIAL, nice quarterly increase.
    24 Jul 2013, 04:48 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs